Novavax $NVAX Stock Volatile On COVID-19 Vaccine Results
Wow. NVAX stock went on a crazy ride on August 4, 2020, after the company reported phase 1 data of its COVID-19 trial. The stock fell -20% after the press
Category
Biotechnology
Fulgent Genetics $FLGT Stock Up In After-hours on 105% Rev Growth
FLGT stock surged 15% higher in after-hours trading on August 4, 2020, after the company released quarterly financials.
Fulgent Genetics, Inc. (NASDAQ: FLGT), a technology company providing comprehensive testing solutions through
Rigel Pharmaceuticals $RIGL Stock Up In After-hours On Beats
RIGL stock is up 19% in after-hours trading on August 4, 2020, after the company reported earnings and revenue beats.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the
Amarin $AMRN Stock Headfake On Quarterly Report
AMRN stock demonstrates the danger of the current trading environment. Amarin's quarterly report was good and the company updated investors on its roll-out plans for Vascepa. The stock would normally
$PFE $BNTX $MRNA Fauci Hopes to Have Covid Vaccine End of Year
Jul.31 -- Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, says he's "cautiously optimistic" to have a Covid-19 vaccine by the end of the year or early next year. Source: https://www.youtube.com/watch?v=VAEU1JRY1zY
Qualigen Therapeutics $QLGN Churning In Pre-market On FastPack COVID-19 Test
QLGN stock churned in pre-market trading on July 30, 2020, after the company sent out a press release that it was now shipping its FastPack COVID-19 antibody test.
Qualigen Therapeutics, Inc.
ADMA Biologics $ADMA Stock Up On Front-Running Ahead of Earnings
ADMA stock rose in after-hours trading on July 29, 2020, after the company announced it was reporting next week on August 5, 2020.
The move in after-hours trading looks like classic
MediciNova Stock $MNOV Explodes Higher
MNOV stock exploded higher in morning trade on July 27, 2020, on news of the company's SARS-CoV-2 Vaccine Joint Development with BioComo and Mie University Japan.
MediciNova, Inc., a biopharmaceutical company
Moderna $MRNA CEO Stephane Bancel on Phase 3 COVID-19 Vaccine
Moderna announced Monday it had received an additional $472 million from the U.S. government to support the company's late-stage development of its vaccine including the phase three study, which began Monday and will include more than 30,000 participants. Moderna CEO Stephane Bancel joins "Squawk Box" to discuss. Source: https://www.youtube.com/watch?v=EtBSCjx1Nqk
$PDSB Stock Up On COVID-19 Vaccine Pre-clinical Data
PDSB stock rose in pre-market trading on July 27, 2020, after the company announced pre-clinical data.
PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious